Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 5/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.59 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.59 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL633987 | 0.84 | PIK3CD (0.67) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL23699115 | 0.84 | PIK3CD (0.48) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL5462197 | 0.82 | GPR119 (0.51) | PIK3CDGPR119 | |
| SCHEMBL23707520 | 0.82 | IDO1 (0.52) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL29862872 | 0.82 | GPR119 (0.51) | PIK3CDGPR119 | |
| SCHEMBL19297216 | 0.82 | GPR119 (0.50) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL4470775 | 0.81 | GPR119 (0.51) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL28775154 | 0.81 | GPR119 (0.59) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL29808551 | 0.81 | GPR119 (0.59) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL20183390 | 0.81 | JAK3 (0.57) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210379052-A1 | QUINOLINE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITORY ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2021-12-09 | — | — | US | disclosed |
| EP-3858813-A1 | QUINOLONE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITED ACTIVITY | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-8680114-B2 | AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2010-07-01 | — | — | US | disclosed |
| EP-1684694-A2 | AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | ARRAY BIOPHARMA INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005051304-A2 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | PIK3CD 38/4885PIK3CA 13/4885PIK3CB 53/4885 |
| US-20210379052-A1 | QUINOLINE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITORY ACTIVITY | IDO1, IDO2, INMT | PIK3CD 2892/4885PIK3CA 3794/4885PIK3CB 3030/4885 |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | PIK3CD 38/4885PIK3CA 13/4885PIK3CB 53/4885 |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | PIK3CD 38/4885PIK3CA 13/4885PIK3CB 53/4885 |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | MTOR, CDK2, CLK2 | PIK3CD 216/4885PIK3CA 130/4885PIK3CB 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.